GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellular Biomedicine Group Inc (NAS:CBMG) » Definitions » ROC %

Cellular Biomedicine Group (Cellular Biomedicine Group) ROC % : -68.09% (As of Sep. 2020)


View and export this data going back to 2007. Start your Free Trial

What is Cellular Biomedicine Group ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Cellular Biomedicine Group's annualized return on capital (ROC %) for the quarter that ended in Sep. 2020 was -68.09%.

As of today (2024-05-07), Cellular Biomedicine Group's WACC % is 0.00%. Cellular Biomedicine Group's ROC % is 0.00% (calculated using TTM income statement data). Cellular Biomedicine Group earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Cellular Biomedicine Group ROC % Historical Data

The historical data trend for Cellular Biomedicine Group's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellular Biomedicine Group ROC % Chart

Cellular Biomedicine Group Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -63.43 -74.90 -80.43 -76.43 -71.98

Cellular Biomedicine Group Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -85.73 -64.43 -54.32 -63.04 -68.09

Cellular Biomedicine Group ROC % Calculation

Cellular Biomedicine Group's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2019 is calculated as:

ROC % (A: Dec. 2019 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2018 ) + Invested Capital (A: Dec. 2019 ))/ count )
=-50.992 * ( 1 - -0% )/( (58.683 + 82.996)/ 2 )
=-50.992/70.8395
=-71.98 %

where

Cellular Biomedicine Group's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2020 is calculated as:

ROC % (Q: Sep. 2020 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2020 ) + Invested Capital (Q: Sep. 2020 ))/ count )
=-70.748 * ( 1 - 0% )/( (87.79 + 120.008)/ 2 )
=-70.748/103.899
=-68.09 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2020) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cellular Biomedicine Group  (NAS:CBMG) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Cellular Biomedicine Group's WACC % is 0.00%. Cellular Biomedicine Group's ROC % is 0.00% (calculated using TTM income statement data). Cellular Biomedicine Group earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Cellular Biomedicine Group ROC % Related Terms

Thank you for viewing the detailed overview of Cellular Biomedicine Group's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellular Biomedicine Group (Cellular Biomedicine Group) Business Description

Traded in Other Exchanges
N/A
Address
1345 Avenue of Americas, 15th Floor, New York, NY, USA, 10105
Cellular Biomedicine Group Inc is a biotechnology company focused on the development of proprietary cell therapies for the treatment of cancer and degenerative diseases. The company has two major cell platforms: immune cell therapy for treating a broad range of cancers using cancer vaccines, Chimeric Antigen Receptor T-cell technologies, and anti-PD-1 technologies; and human-adipose-derived mesenchymal progenitor cells for treatment of joint and autoimmune diseases. The immuno-oncology and stem cell research team is based in both China and the United States.
Executives
Ag Novartis 10 percent owner LICHTSTRASSE 35, BASEL V8 CH 4056
Pharma Ag Novartis 10 percent owner LICHTSTRASSE 35, CH-4002, BASEL V8
Edward T Schafer director 1400 31ST AVENUE SW, SUITE 60, MINOT ND 58701
Wen Tao Liu director 530 UNIVERSITY AVENUE, #17 PALO ALTO CA 94301
Terry Belmont director 530 UNIVERSITY DRIVE PALO ALTO CA 94301
Au Chun Kwok Alan director C/O CELLULAR BIOMEDICINE GROUP, INC. 530 UNIVERSITY AVENUE, #17 NEW YORK NY 94301
Hansheng Zhou director 369 LUMO ROAD HONGSHAN DISTRICT WUHAN F4 430074
Gang Jacky Ji director XIXI RONGZHUANG 27-3 JINGCHANG ROAD, YUHANG DISTRICT, HANGZHOU, ZHEJIANG F4 311100
Viktor Pan 10 percent owner HELI XI LU 183 NO. 531 SHANGHAI F4 201317
Srl Opea director VIA CESARE BATTISTA 1 MILAN L6 20122
Zheng Zhou 10 percent owner FLAT B, 25/F, TOWER 6, MARINELLA 9 WELFARE ROAD, ABERDEEN HONG KONG K3 00000
Sailing Capital Overseas Investments Fund, Lp 10 percent owner C/O UNIT 2006-08, 20F HARBOUR CENTRE 25 HARBOUR ROAD WAN CHAI K3 00000
Maplebrook Ltd 10 percent owner P.O. BOX 31119 GRAND PAVILLION HIBISCUS WAY, 802 WEST BAY ROAD GRAND CAYMAN E9 KY1-1205
Tf Venture Capital Management Co., Ltd. 10 percent owner PO BOX 472, 2ND FLOOR, HARBOUR PLACE 103 SOUTH CHURCH STREET, GEORGE TOWN GRAND CAYMAN E9 KY1-1106
Winsor Capital Ltd 10 percent owner TRINITY CHAMBERS PO BOX 4301, ROAD TOWN TORTOLA D8 00000

Cellular Biomedicine Group (Cellular Biomedicine Group) Headlines

From GuruFocus